AMY-101 | CAS#1427001-89-5 | peptidic inhibitor

MedKoo Cat#: 461677 | Name: AMY-101

Description:

WARNING: This product is for research use only, not for human or veterinary use.

AMY-101 is a peptidic inhibitor of the central complement component C3.

Chemical Structure

AMY-101

CAS#1427001-89-5 (free base)

Theoretical Analysis

MedKoo Cat#: 461677

Name: AMY-101

CAS#: 1427001-89-5 (free base)

Chemical Formula: C83H117N23O18S2

Exact Mass: 1787.8388

Molecular Weight: 1789.11

Elemental Analysis: C, 55.72; H, 6.59; N, 18.01; O, 16.10; S, 3.58

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

1789738-04-0 (TFA) 1427001-89-5 (free base)

Synonym

AMY-101; AMY 101; AMY101;Compstatin 40; CP40; CP 40; CP-40;

IUPAC/Chemical Name

2-((4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-10-((1H-imidazol-5-yl)methyl)-19-((1H-indol-3-yl)methyl)-34-((2S,3S)-2-((R)-2-amino-3-(4-hydroxyphenyl)propanamido)-3-methylpentanamido)-4-(((2S,3S)-1-amino-3-methyl-1-oxopentan-2-yl)(methyl)carbamoyl)-25-(3-amino-3-oxopropyl)-7-(3-guanidinopropyl)-31-isopropyl-13,17-dimethyl-28-((1-methyl-1H-indol-3-yl)methyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decaazacyclopentatriacontan-22-yl)acetic acid

InChi Key

MUSGYEMSJUFFHT-UWABRSFTSA-N

InChi Code

InChI=1S/C83H117N23O18S2/c1-11-43(5)68(103-72(114)53(84)30-46-23-25-50(107)26-24-46)80(122)100-61-39-125-126-40-62(82(124)106(10)69(70(86)112)44(6)12-2)101-73(115)55(21-17-29-90-83(87)88)94-76(118)58(33-49-36-89-41-92-49)96-71(113)45(7)93-65(109)38-105(9)81(123)60(31-47-35-91-54-20-15-13-18-51(47)54)99-77(119)59(34-66(110)111)97-74(116)56(27-28-64(85)108)95-75(117)57(98-79(121)67(42(3)4)102-78(61)120)32-48-37-104(8)63-22-16-14-19-52(48)63/h13-16,18-20,22-26,35-37,41-45,53,55-62,67-69,91,107H,11-12,17,21,27-34,38-40,84H2,1-10H3,(H2,85,108)(H2,86,112)(H,89,92)(H,93,109)(H,94,118)(H,95,117)(H,96,113)(H,97,116)(H,98,121)(H,99,119)(H,100,122)(H,101,115)(H,102,120)(H,103,114)(H,110,111)(H4,87,88,90)/t43-,44-,45-,53+,55-,56-,57-,58-,59-,60-,61-,62-,67-,68-,69-/m0/s1

SMILES Code

O=C(O)C[C@H](NC([C@H](CCC(N)=O)NC([C@H](CC1=CN(C)C2=C1C=CC=C2)NC([C@H](C(C)C)N3)=O)=O)=O)C(N[C@@H](CC4=CNC5=C4C=CC=C5)C(N(C)CC(N[C@@H](C)C(N[C@@H](CC6=CN=CN6)C(N[C@@H](CCCNC(N)=N)C(N[C@H](C(N([C@@H]([C@@H](C)CC)C(N)=O)C)=O)CSSC[C@H](NC([C@@H](NC([C@H](N)CC7=CC=C(O)C=C7)=O)[C@@H](C)CC)=O)C3=O)=O)=O)=O)=O)=O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,789.11 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Kajikawa T, Briones RA, Resuello RRG, Tuplano JV, Reis ES, Hajishengallis E, Garcia CAG, Yancopoulou D, Lambris JD, Hajishengallis G. Safety and Efficacy of the Complement Inhibitor AMY-101 in a Natural Model of Periodontitis in Non-human Primates. Mol Ther Methods Clin Dev. 2017 Aug 18;6:207-215. doi: 10.1016/j.omtm.2017.08.001. eCollection 2017 Sep 15. PubMed PMID: 28879212; PubMed Central PMCID: PMC5577415. 2: Mastellos DC, Reis ES, Yancopoulou D, Hajishengallis G, Ricklin D, Lambris JD. From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage. Immunobiology. 2016 Oct;221(10):1046-57. doi: 10.1016/j.imbio.2016.06.013. Epub 2016 Jun 16. Review. PubMed PMID: 27353192; PubMed Central PMCID: PMC4987232. 3: Mastellos DC, Ricklin D, Yancopoulou D, Risitano A, Lambris JD. Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape. Expert Rev Hematol. 2014 Oct;7(5):583-98. doi: 10.1586/17474086.2014.953926. Epub 2014 Sep 2. Review. PubMed PMID: 25213458; PubMed Central PMCID: PMC4383744. 4: Mastellos DC, Reis ES, Ricklin D, Smith RJ, Lambris JD. Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery. Trends Immunol. 2017 Jun;38(6):383-394. doi: 10.1016/j.it.2017.03.003. Epub 2017 Apr 14. PubMed PMID: 28416449; PubMed Central PMCID: PMC5447467.